


## PHARMACEUTICAL 2021



## PLIANT THERAPEUTICS INC. Rank 56 of 409





## PHARMACEUTICAL 2021



## PLIANT THERAPEUTICS INC. Rank 56 of 409



The relative strengths and weaknesses of PLIANT THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PLIANT THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 100% points. The greatest weakness of PLIANT THERAPEUTICS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 93%, being 447% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	290,754
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,599
Liabilities, Non-Current	866
Other Assets	451
Other Compr. Net Income	-31
Other Expenses	0
Other Liabilities	0
Other Net Income	112
Property and Equipment	4,321
Research and Development	66,193
Revenues	41,817
Selling, General and Administrative Expense	17,269

Output Variable	Value in 1000 USD
Assets	295,526
Liabilities	12,465
Expenses	83,462
Stockholders Equity	283,061
Net Income	-41,533
Comprehensive Net Income	-41,548
Economic Capital Ratio	93%